Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Total Liabilities
Everything the company owes to creditors and other parties.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 107.3% from a year ago
Total liabilities stood at $39.64M at the end of Q1 FY2026, up 107.3% from a year earlier and up 34.2% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.
Context
- Total liabilities amounted to 7.2% of total assets at the end of Q1 FY2026, up 3.2 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +107.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 29.54M USD
- Year-over-year change
- -61.8%
- 3-year CAGR
- +7.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.54M | -61.8% |
| FY2024 | 2024-12-31 | 77.32M | +399.7% |
| FY2023 | 2023-12-31 | 15.47M | -35.5% |
| FY2022 | 2022-12-31 | 23.98M | — |
Total Liabilities vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 total liabilities of $39.64M is the 2nd highest of the 6 companies compared; the peer median is $18.7M.
- Its year-over-year change of +107.3% is the 3rd highest of 6, against a peer median of +35.2%.
- Total liabilities amounts to 7.2% of total assets for BCAX, versus a peer median of 9.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $196.68M | +35.2% | +10.9% | 90.3% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $39.64M | +107.3% | +7.2% | 7.2% |
| Mar 2026 | $36.81M | +32.2% | +15.0% | 9.1% | |
| Mar 2026 | $18.7M | -11.7% | +8.2% | 9.1% | |
| Mar 2026 | $15.28M | +484.0% | +61.3% | 7.7% | |
| Mar 2026 | $6.66M | +235.7% | +35.7% | 11.3% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $18.7M | +35.2% | +15.0% | 9.1% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.